This was particularly evident among low-grade gliomas, where only 32% of low-grade IDH1/2-mutant gliomas were assessed for MGMT-methylation status compared to 52% of high-grade and 82% of grade 4 IDH1/2-mutant gliomas. This evidence concerns the gene MGMT and central nervous system cancer.